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Abstract Management of a sporadic vestibular schwan-
noma (VS) is still a subject of controversy, mainly due to
distinct and unpredictable growth patterns. To embark on
an appropriate therapy it is necessary to dispose of a reli-
able prediction about tumor progression. This study aims to
design a risk proWle with predictors for VS growth. A total
of 234 VS patients who were managed conservatively were
included. Data concerning (duration of) symptoms and
localization of VS were analyzed with Cox proportional
hazards regression models. Predictors for growth are
unsteadiness/vertigo, no sudden onset of hearing loss and
short duration of hearing loss. High-risk patients have (1)
VS with an extrameatal localization, short duration of hear-
ing loss and at least one of the two other predictors
(unsteadiness/vertigo or no sudden sensorineural hearing
loss) or (2) VS with an intrameatal localization and all three
other predictors. Low-risk patients have (1) VS with an
extrameatal component and no other predictor or (2) VS with
an intrameatal localization and at most one other predictor.
High-risk patients have a risk of growth of 36.9% in the
Wrst year and 64.6% in the second year. For patients with a
low risk this is 2.5 and 12.7%, respectively. Simple data
gathered at the moment of diagnosis may provide useful
information since they may lead to a risk proWle for growth.
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Introduction
The management of a unilateral sporadic vestibular
schwannoma (VS) is still a subject of controversy mainly
due to distinct and unpredictable growth patterns. In case of
a solid VS a wait-and-scan-policy is often appropriate
because these tumors in general show no growth or have a
slow growth pattern, varying between 0.9 and 1.9 mm in
maximal diameter per year [1–4]. Moreover, several studies
on the growth rate of VSs, have shown besides stability
even regression during conservative management [1, 5–10].
In contrast, part of the solid VSs is able to present with rel-
atively rapid growth, which eventually might result in seri-
ous morbidity and even mortality if left untreated.
To embark on the most appropriate management of VSs
it is necessary to dispose of a reliable prediction about the
growth of the tumor at the moment of diagnosis.
This study is aimed to design a risk proWle for VS
growth based on anamnestic and radiological data gathered
at the moment of diagnosis, that is (duration of) symptoms
and localization of the tumor.
Materials and methods
Study group
A prospective study of patients with sporadic unilateral
VSs was conducted at the department of otorhinolaryngol-
ogy of the Radboud University Medical Centre Nijmegen,
The Netherlands. Patients with sporadic unilateral VS were
included from 1994 to 2006. The diagnosis of VS was
based on characteristic symptoms, audiovestibular data and
MR images. Patients who were initially managed conserva-
tively were included. Conservative management consisted
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scans. The treatment protocol for VS in our institute is
highly individualized and Xexible, particularly after inform-
ing the patient. The management is determined after con-
sidering a 10-points paradigm which includes tumor size,
unfavorable health factors, invalidating symptoms, duration
of symptoms, hearing level, contralateral hearing, tinnitus,
balance problems, documented tumor growth and personal
preferences of the patient. As a consequence, the manage-
ment is tailored to the patient instead of being the result of a
rigidly shaped protocol. Patients with other ear pathologies
than a VS and patients with neuroWbromas were not
selected. Patients with cystic tumors were excluded. Cystic
tumors were deWned as solid tumors demonstrating cystic
components Wlled with a Xuid-like substance on the outer
aspect of the tumor, as visualized with MRI.
The following patient characteristics were addressed in
this study; gender, age at the moment of diagnosis, (duration
of) symptoms, tumor side (left or right) and localization of
the tumor. A classiWcation was made into purely intrameatal
(IAC group) or intrameatal and extrameatal [cerebellopon-
tine angle (CPA) group]. The distinction between these two
groups was made on the basis of the axial MR-images. The
tumor was assigned to the IAC group when the protrusive
tumor surface was less then one-third of the intrameatal
tumor surface, as depicted in the axial plane with MRI. The
duration of symptoms was deWned as the time between the
onset of Wrst symptoms and the diagnosis.
Analysis of tumor growth
MRI was used to assess the size of the lesions. The size of
the IAC tumors was taken as the maximum diameter along
the length of the IAC. The diameters of the CPA tumors were
measured by two diVerent methods due to diVerent observ-
ers. Method 1 consisted of measuring of the maximum diam-
eter parallel to the petrous ridge in the axial plane; method 2
consisted of taking the maximum diameter parallel to the
internal auditory canal in the axial plane. It is known that VS
have diVerent growth patterns. Some will show growth
within the Wrst year of observation; some will show growth
after some years. Therefore, the time to Wrst observed growth
as assessed by MRI was recorded. The deWnition of growth
was determined by the diVerence in tumor size of ¸1 mm in
the axial plane. Growth was determined by means of inde-
pendent assessments by a radiologist and an otolaryngologist.
Audiometry
Pure-tone audiometry
The audiometric assessments of the pure tone audiometry
complied with the highest clinical standards. The Fletcher
Index (FI) of air conduction of the VS-ear was included. FI
was deWned as the mean of the thresholds at 500, 1000 and
2000 Hz. When no threshold could be assessed in the pure-
tone audiogram, it was noted at 130 dB HL.
Speech audiometry
Speech audiometry measurements with Dutch vowel-con-
sonant-vowel words were performed up to a maximum of
125 dB SPL.
Statistical analysis
Statistical analysis was performed using SPSS 12.0. The
occurrence of growth of the VS is dependant on the param-
eter “duration of follow-up”. Some VS grow constantly;
some VS start to grow after a period of stability and some
VS stay stable. It would be inadequate to simply compare
VSs in classes of “growth” and “no growth” because not all
VS patients had the same period of follow-up. Therefore,
the time elapsed until the Wrst observed growth was pre-
sented in a Kaplan–Meier curve with censoring at the time
of the last MRI when no growth was observed.
The association of potential risk factors with the risk of
growth was examined with Cox proportional hazards
regression models. Hazard rate ratios (HRR) were calcu-
lated to quantify the eVect of a risk factor on growth. First,
within each set of factors like localization (IAC or CPA),
symptoms and duration of symptoms, the risk factors were
selected using backward elimination. The selected risk
factors were then combined in another backward selection
procedure to yield the Wnal model. Based on the Wnal
model regression scores can be calculated for each patient
(P < 0.05). Patients were categorized according to quin-
tiles of the regression score, with the lowest quintile
labeled low-risk and the top quintile labeled high risk.
Cumulative probability curves were constructed for




Prospectively 382 VS cases were considered. Conservative
treatment was initially applied in 283 patients. The main
reason for conservative treatment was small tumor size
(n = 236). Some patients refused any treatment (n = 8),
another group was managed conservatively because of co-
morbidity (n = 10) and some patients were treated conser-
vatively because of a long history of symptoms suggesting
a slow growth pattern or absence of growth (n = 26). A123
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fore treated conservatively.
The remaining 99 patients were primarily treated by
microsurgery (n = 84), stereotactic radiotherapy (n = 10)
treatment or a combination of surgery and stereotactic
radiotherapy (n = 5).
The indications for primary treatment of the VS was a
large tumor size (n = 63), personal preference of the patient
(n = 16), the aim of hearing preservation (n = 2) and the
presence of debilitating audiovestibular symptoms (n = 3).
After exclusion of patients without a second scan
(n = 38) and patients with cystic tumors (n = 11), the study
group comprised 234 sporadic unilateral VS patients
(Table 1). The mean age at the moment of diagnosis was
57 years (SD 11.79, range: 16–82 years), 55 years (SD
12.04, range: 16–77 years) for men and 60 years (SD 11.10,
range: 30–82 years) for women. The distribution of the
tumor localization obtained by the Wrst MRI was as fol-
lows: 142 intrameatal and 92 intrameatal with extension
into the cerebellopontine angle. The mean follow-up of
these patients with conservative management was
28 months (SD: 20.89, range: 4–120 months).
Tumor characteristics
No signiWcant diVerence in gender, age or side of the tumor
was found between patients with and without growth of the
tumor or between IAC and CPA localization. The mean
maximum diameter of the IAC tumors was 9.2 mm (SD:
3.29, range 2.00–14.00 mm). The mean maximal diameter
of the CPA tumors measured with method 1 was 12.2 mm
(SD: 4.31, range 5.00–23.00 mm). The tumors measured
with method 2 had a mean maximal diameter of 17.2 mm
(SD: 4.92, range 10.00–30.00 mm).
Clinical presentation
The symptoms reported by patients at the moment of diag-
nosis are shown in Table 2. The most reported symptoms at
their Wrst visit to the hospital were hearing loss, tinnitus and
unsteadiness/vertigo. Also sudden sensorineural hearing
loss (SSHL) and aural fullness were a rather common pre-
senting symptom in 13.2 and 11.5% of the patients, respec-
tively. The mean duration of all symptoms was 60 months
(SD 80.42, range 1–480 months). In the total patient popu-
lation sample hearing loss had the longest duration amongst
other symptoms (Table 3).
In the study group no other otologic disorders were
present.
Audiometry
Pure tone audiometry data of 231 patients was available.
Data of the audiometry results for the VS-ear are presented
in Table 4. The mean FI was 38.9 dB HL (SD 25.98 dB
HL). In six patients total deafness of the VS-ear was found
(FI ¸ 130 dB HL). Speech recognition audiometry data of
211 patients were available. The mean Pbmax was 70.0%
(SD 29.85) (Table 4).
Risk of growth
The risk of growth in the Wrst year after diagnosis regarding
the whole study population sample is 17% and is increasing
during follow-up. Within 2 years the risk increases to 38%
and within 5 years it increases to 58%. Tumors with an ini-
tial IAC localization have a 10% risk of growth within
1 year compared to 28% for tumors with an initial CPA
localization. Within 3 years this risk is 43% compared to
64% for intrameatal and extrameatal tumors, respectively.
Within 5 years the risk seems stable for patients with
intrameatal tumors (49%) and seems to increase for patients
with extrameatal tumors (73%). This results in a HRR of
2.0 for growth (P < 0.05) for patients with a VS with exten-
sion into the cerebellopontine angle compared to patients
with a VS which is limited to the internal auditory canal
(Fig. 1).
Table 1 Patient characteristics
IAC internal auditory canal, CPA cerebellopontine angle (for deWni-
tions see “Materials and methods”)
Total Localization of VS
IAC CPA
Number of patients 234 142 92
Mean age at diagnosis 
(years) (SD)
57 (11.79) 57 (11.52) 59 (12.16)
Mean follow-up 
(months) (SD)
28 (20.89) 31 (22.50) 24 (17.35)
Gender (male:female) 119:115 71:71 48:44
Side VS (right:left) 121:113 76:66 45:47
Table 2 Frequencies of symptoms
SSHL sudden sensorineural hearing loss
Symptoms Total
n = 234 (%)
Localization of VS
IAC
n = 142 (%)
CPA
n = 92 (%)
Hearing loss 216 (92.3) 128 (90.1) 88 (95.7)
Tinnitus 151 (64.5) 93 (65.5) 58 (63.0)
Unsteadiness/vertigo 103 (44.0) 59 (41.5) 44 (47.8)
SSHL 31 (13.2) 20 (14.1) 11 (12.0)
Aural fullness 27 (11.5) 19 (13.4) 8 (8.7)
Otalgia 10 (4.3) 5 (3.5) 5 (5.4)
Headache 8 (3.4) 3 (2.1) 5 (5.4)123
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The following potential risk factors are retained as predic-
tors of growth in backward elimination models: an extram-
eatal localization of VS and among symptoms, tinnitus,
unsteadiness/vertigo, no SSHL and a short duration of hear-
ing loss. This short duration is deWned as a hearing loss of
just 1–24 months.
The Wnal model is based on population sample of 224
patients; in 10 patients no information about duration of
symptoms was reported. The following predictors of
growth are included in the model 1: extrameatal localiza-
tion (HRR 2.3, P < 0.0001), 2: no SSHL (HRR 0.5,
P < 0.05), 3: unsteadiness/vertigo (HRR 2.0, P < 0.001)
and 4: short duration of hearing loss (1–24 months) (HRR
3.1 (P < 0.0001). The symptom tinnitus as predictor of
growth had no contributory eVect to the model. Based on
this Wnal model 16 classes of patients with diVerent risk
proWles can be deWned. We categorized the patients accord-
ing to quintiles of the regression score. The cumulative
probability of growth for each quintile is obtained with the
Kaplan–Meier method. The following risk proWles were
deWned (1) high-risk (n = 43), (2) intermediate risk
(n = 139) and (3) low-risk (n = 42). The patients with a
high and low-risk for growth of VS are shown in Table 5.
For patients with a low-risk proWle the risk of growth of
a VS is 2.5% in the Wrst year and 12.7% within 2 years. For
patients with a high-risk proWle the risk of growth of a VS
in the Wrst year is 36.9 and 64.6% within 2 years (Fig. 2).
Discussion
Vestibular schwannomas are mostly slow growing tumors.
Conservative management with regularly MRI-scanning is
an appropriate approach because any type of therapy may
result into (increased) hearing loss or facial nerve deWcits.
However, some VS present with rapid growth that may lead
to serious morbidity and even mortality if left untreated.
Preferably, the growth behavior of VS should be predict-
able at the moment of diagnosis to allow the best strategy.
Throughout the years, several studies attempted to identify
growth predictors of VSs. Due to diVerent research hypoth-
eses and protocols the results of these studies are hardly
comparable. The size of the tumor at the moment of diag-
nosis has been proposed as an indicator for growth. Fucci
et al. [11] reported a signiWcantly increased growth rate of
tumors with a maximal diameter larger than 20 mm at pre-
sentation. Some studies found that tumor growth in the Wrst
year could be indicative for future growth [12, 13]. Further-
more the symptoms of the patients have been considered as
possible predictors of growth. Tschudi et al. [13] found that
patients with progressive hearing loss as a Wrst symptom
had a signiWcantly lower tumor growth than those present-
ing with tinnitus, sudden hearing loss and vertigo. Other
studies, however, revealed no signiWcant diVerences in age,
gender, tumor laterality, initial symptoms, duration of
symptoms or initial tumor size between patients with grow-
ing tumors and non-growing tumors [7, 11, 12, 14]. A pos-
sible predictor of growth may be the duration of symptoms.
One study reported that patients with a short duration of
symptoms had tumors that signiWcantly grew faster [15].
Our study demonstrated that the symptom hearing loss was
Table 3 Mean duration of symptoms
SSHL sudden sensorineural hearing loss
a








Hearing loss 55 (76.9) 48 (74.84) 65 (79.15)
Tinnitus 37 (56.80) 31 (51.02) 47 (64.32)
Unsteadiness/vertigo 39 (68.43) 38 (65.32) 40 (37.65)
SSHL 28 (58.34) 17 (41.84) 41 (73.90)
Aural fullness 21 (25.79) 14 (14.94) 50 (41.68)
Otalgia 7.0 (6.61) a a
Headache 32 (48.98) a a
Table 4 Audiometry data of the ear with VS








FI (dB HL) 38.9 (25.98) 36.9 (26.18) 42.0 (25.50)
Pbmax (%) 70.0 (29.85) 73.3 (28.61) 65.0 (31.15)
Fig. 1 Risk of growth for VS with intrameatal versus extrameatal
localization at the moment of diagnosis

























k s i r   ta   .o N 
2 9   -a r t x E 
2 4 1   -a r t n I 
1 
5 5   
9 1 1 
2 
9 2   




2 3   
4 
6    
3 2   
5 
4    
5 1   
6 
1   
01 123
Eur Arch Otorhinolaryngol (2009) 266:641–646 645present in 92.3% of the patient population sample and that
short duration of hearing loss was indeed a predictor of
growth with a hazard risk of 3.1 (P < 0.0001).
The search for predictors of growth should result in a man-
ageable proWle which could be implied in practice. Such a
proWle can be performed by using statistical tests like regres-
sion or multivariate analysis. Beenstock [16] used a multivari-
ate analysis to investigate predictors for VS growth. However,
this study was based on two independent sets of previous data
with a small number of patients (n = 51 and n = 69). Age, side
of the tumor and reporting symptoms seemed to be key vari-
ables in predicting stability or growth of VS [16]. If reporting
symptoms included vertigo and unsteadiness in tumor growth
was more pronounced. This could be conWrmed in our study:
the hazard risk for growth for the symptom unsteadiness/ver-
tigo was 2.0. Beenstock [16] found that probability of stability
seemed to be independent of gender, tinnitus and hearing loss.
This is also in accordance with the results found in our study
except for tinnitus which was retained as a predictor for
growth. In this study side of the tumor was not indicative as a
potential risk factor for growth. Beenstock [16] reported that
left side of the tumor was an indicator for growth of VS. Fur-
thermore in one data set VS growth varied signiWcantly and
inversely with age.
This study was able to present a risk proWle of VS
growth concerning initial symptoms and localization of VS.
In contrast to results of earlier studies, we demonstrated
that symptoms reported by patients at the moment of diag-
nosis seem to be of great value in predicting growth behav-
ior of VS. More attention need to be given to initial
symptoms such as unsteadiness or vertigo, tinnitus, short
duration of hearing loss or the absence of SSHL. This in
combination with the localization of the VS as seen on the
Wrst MRI might be of importance considering treatment
options for VS. To our knowledge this is the Wrst study that
presents a risk proWle for VS growth based on information
gathered at the moment of diagnosis.
The statistical grouping of patients in three risk groups
and comparing the high and low-risk groups eliminated a
considerable amount of patients from the study. However,
this grouping was essential in order to distinguish relevant
diVerences. The outline of the statistical analysis was
shaped in such a way that the eVects of the various determi-
nants could be visualized.
Studies concerning the prediction of stability or growth
of VSs should ideally be done with random patient selec-
tion. The non-random selection method might have resulted
in overstatement of stability of the VS and understatement
of initial symptoms. In clinical practice, however, a random
selection of patients with VS is not feasible, because some
VSs have such large size that surgery instead of conserva-
tive management is the treatment of Wrst choice. The diVer-
ences between the treated and non-treated groups of
patients were quite variable and not uniformly categorized.
This makes that some degree of similarity between those
two groups is certainly present. As a result the outcomes of
this longitudinal study should be considered as being repre-
sentative or at least indicative for the whole VS population.
Conclusion
This study presents a risk proWle for VS growth based on
symptoms and localization of the tumor in a non-random-
ized study group managed by a “wait and scan” policy.
Patients with a high-risk proWle have a risk of growth of
36.9% in the Wrst year and 64.6% within 2 years. To this
risk proWle belong patients with (1) VS with an extrameatal
component and short duration of hearing loss and at least
one of the two predictors (unsteadiness/vertigo or no
Table 5 Risk proWle of patients 
with VS High risk Low risk
1. VS with an extrameatal component and
Short duration of hearing loss and
At least one of the other two predictors 
(unsteadiness/vertigo or no SSHL)
1. VS with an extrameatal component and
No other predictor
2. VS with intrameatal localization and
All three other predictors
2. VS with an intrameatal localization and
At most one other predictor
The predictors for growth are ex-
trameatal localization and 
among symptoms, short duration 
of hearing loss (1–24 months), 
unsteadiness/vertigo, no SSHL
Fig. 2 Patients with high and low-risk of growth of VS. High-risk and














































646 Eur Arch Otorhinolaryngol (2009) 266:641–646SSHL), (2) VS with intrameatal localization and all three
other predictors (short duration of hearing loss, unsteadi-
ness/vertigo, no SSHL). For patients with a low-risk proWle
the risk of growth in the Wrst year is 2.5 and 12.7% within
2 years. These patients have (1) VS with an extrameatal
component and no other predictor or (2) VS with an intram-
eatal localization and at most one other predictor.
The outcomes of this study cannot directly be general-
ized for the whole VS population. Nevertheless, they are
indicative for the behavior of these tumors.
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